J. Molner AS announced it has entered into an agreement with the US Centers for Medicaid and Medicare Services (CMS). This will see J. Molner providing rebates to all states with a Medicaid State Plan, enhancing the affordability of its high-quality generic medications for millions of Americans. The Medicaid Drug Rebate Program is a pivotal component of the US healthcare system, requiring drug manufacturers to offer rebates on outpatient drugs to state Medicaid programs. In exchange, states provide coverage for these drugs to their Medicaid enrollees.

This program is vital for ensuring that essential medications are accessible to the low-income population, a principle that aligns with J. Molner's mission to deliver affordable healthcare solutions. Implementation of J. Molner's participation across all US states is underway, with each state adopting the Molner rebate program in phases. The process is expected to be fully complete by the end of March 2024, marking a significant step forward in efforts to support healthcare affordability and access in the United States.